Wu, Y., Xu, Z., Arshad, B., Wu, J., Zhang, K., Wu, H., . . . Kong, L. (2018). Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials. J Cancer.

Wu, Yu-tuan, et al. "Significantly Higher Pathologic Complete Response (pCR) After the Concurrent Use of Trastuzumab and Anthracycline-based Neoadjuvant Chemotherapy for HER2-positive Breast Cancer: Evidence From a Meta-analysis of Randomized Controlled Trials." J Cancer 2018.

Wu, Yu-tuan, et al. "Significantly Higher Pathologic Complete Response (pCR) After the Concurrent Use of Trastuzumab and Anthracycline-based Neoadjuvant Chemotherapy for HER2-positive Breast Cancer: Evidence From a Meta-analysis of Randomized Controlled Trials." J Cancer 2018.